Pipeline updates are highly awaited events in the
pharma/biotech sector as they play an important role in deciding
whether or not to invest in a particular company. Pipelines are
of prime importance as far as pharma/biotech companies are
concerned. These companies spend a significant amount in
advancing their pipelines.
Dynavax Technologies Corp.
) recently received a $5.4 million milestone payment from
We note that Dynavax entered into a three-year research
collaboration and license agreement with AstraZeneca in Sep 2006
for the discovery and development of TLR9 agonist-based therapies
for the treatment of asthma and chronic obstructive pulmonary
disease. The agreement was amended in Oct 2011 wherein Dynavax
was responsible for initial development of AZD1419.
Dynavax and AstraZeneca have now further amended their
research collaboration and license agreement. As per the amended
agreement, AstraZeneca is now responsible for further clinical
trials following the completion of the ongoing phase I clinical
study on asthma candidate AZD1419.
We remind investors that Dynavax initiated dosing in a phase I
study in Oct 2013 which is being conducted to assess the safety
of inhaled doses of AZD1419 in up to 45 healthy subjects which
will then be followed by up to 24 patients suffering from mild
Excluding the current payment, Dynavax is entitled to
potential milestone payments of approximately $100 million. In
addition, the company will receive royalties on sales of any
approved products globally along with an opportunity to
co-promote in the U.S.
Meanwhile, Dynavax is striving hard to get its hepatitis B
vaccine candidate, Heplisav, approved in the U.S. and EU.
Since Dynavax does not have any other approved product in its
portfolio, we expect investor focus to remain on Heplisav updates
in the near term.
Dynavax currently carries a Zacks Rank #2 (Buy). Right now,
) also look well placed. Both carry a Zacks Rank #1 (Strong
ASTRAZENECA PLC (AZN): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
DYNAVAX TECH CP (DVAX): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
To read this article on Zacks.com click here.